PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 23374726-9 2013 An approach using PTP1B-directed antisense oligonucleotides is also in phase 2 clinical trials. Oligonucleotides 43-59 protein tyrosine phosphatase, non-receptor type 1 Mus musculus 18-23 16978088-1 2006 Protein-tyrosine phosphatase 1B (PTP1B) inhibitory activity of the 2"-O-(2-methoxy)ethyl (2"- MOE)-modified gapmer antisense oligonucleotide, ISIS113715, was previously reported. Oligonucleotides 125-140 protein tyrosine phosphatase, non-receptor type 1 Mus musculus 0-31 18029611-0 2007 In vivo antisense activity of ENA oligonucleotides targeting PTP1B mRNA in comparison of that of 2"-MOE-modified oligonucleotides. Oligonucleotides 34-50 protein tyrosine phosphatase, non-receptor type 1 Mus musculus 61-66 18029611-1 2007 The 2"-0-(2-methoxy)ethyl (2"-MOE)-modified gapmer antisense oligonucleotide ISIS113715, which targets protein-tyrosine phosphatase IB (PTP1B) mRNA, increases insulin sensitivity and normalizes plasma glucose levels in diabetic ob/ob and db/db mice. Oligonucleotides 61-76 protein tyrosine phosphatase, non-receptor type 1 Mus musculus 136-141 18029611-2 2007 In the present study, the efficacy of the isosequential 2"-O,4"-C-ethylene-bridged nucleic acid (ENA)-modified oligonucleotide ENA-1 was compared with that of ISIS113715 in order to further improve the down-regulation of PTP1B in db/db mice. Oligonucleotides 111-126 protein tyrosine phosphatase, non-receptor type 1 Mus musculus 221-226 16978088-3 2006 In the present study, the isosequential 2"-O,4"-C-ethylene-bridged nucleic acid (ENA)-modified oligonucleotide, ENA-1, was synthesized, and its ability to further improve the downregulation of PTP1B in db/db mice was examined. Oligonucleotides 95-110 protein tyrosine phosphatase, non-receptor type 1 Mus musculus 193-198 12782412-2 2003 Our studies have shown that in insulin resistant and diabetic ob/ob and db/db mice, reducing the levels of protein tyrosine phosphatase 1B (PTP1B) protein by treatment with a PTP1B antisense oligonucleotide resulted in improved insulin sensitivity and normalized plasma glucose levels. Oligonucleotides 191-206 protein tyrosine phosphatase, non-receptor type 1 Mus musculus 107-138 12871138-3 2003 Inhibiting PTP1B action using antisense oligonucleotides and small molecule inhibitors represents novel therapeutic approach for the treatment of insulin resistance, type II diabetes, and obesity. Oligonucleotides 40-56 protein tyrosine phosphatase, non-receptor type 1 Mus musculus 11-16 12649327-2 2003 Treatment of ob/ob mice with protein tyrosine phosphatase 1B (PTP1B) antisense oligonucleotides (ASO) reduced phosphorylation of p38 in liver-to below lean littermate levels-and normalized plasma glucose while reducing plasma insulin. Oligonucleotides 79-95 protein tyrosine phosphatase, non-receptor type 1 Mus musculus 29-60 12649327-2 2003 Treatment of ob/ob mice with protein tyrosine phosphatase 1B (PTP1B) antisense oligonucleotides (ASO) reduced phosphorylation of p38 in liver-to below lean littermate levels-and normalized plasma glucose while reducing plasma insulin. Oligonucleotides 79-95 protein tyrosine phosphatase, non-receptor type 1 Mus musculus 62-67 12782412-2 2003 Our studies have shown that in insulin resistant and diabetic ob/ob and db/db mice, reducing the levels of protein tyrosine phosphatase 1B (PTP1B) protein by treatment with a PTP1B antisense oligonucleotide resulted in improved insulin sensitivity and normalized plasma glucose levels. Oligonucleotides 191-206 protein tyrosine phosphatase, non-receptor type 1 Mus musculus 140-145 12782412-2 2003 Our studies have shown that in insulin resistant and diabetic ob/ob and db/db mice, reducing the levels of protein tyrosine phosphatase 1B (PTP1B) protein by treatment with a PTP1B antisense oligonucleotide resulted in improved insulin sensitivity and normalized plasma glucose levels. Oligonucleotides 191-206 protein tyrosine phosphatase, non-receptor type 1 Mus musculus 175-180 12476961-3 2002 Diabetic mice treated with PTP1B antisense oligonucleotides intraperitoneally have lower PTP1B protein levels in liver and fat, reduced plasma insulin, blood glucose and hemoglobin A1c (HbA1c) levels. Oligonucleotides 43-59 protein tyrosine phosphatase, non-receptor type 1 Mus musculus 27-32 12626322-11 2003 The insulin-sensitive phenotype of the PTP1B knockout mouse is reproduced when the phosphatase is also knocked down with an antisense oligonucleotide in obese mice. Oligonucleotides 134-149 protein tyrosine phosphatase, non-receptor type 1 Mus musculus 39-44 12476961-3 2002 Diabetic mice treated with PTP1B antisense oligonucleotides intraperitoneally have lower PTP1B protein levels in liver and fat, reduced plasma insulin, blood glucose and hemoglobin A1c (HbA1c) levels. Oligonucleotides 43-59 protein tyrosine phosphatase, non-receptor type 1 Mus musculus 89-94 12169659-0 2002 PTP1B antisense oligonucleotide lowers PTP1B protein, normalizes blood glucose, and improves insulin sensitivity in diabetic mice. Oligonucleotides 16-31 protein tyrosine phosphatase, non-receptor type 1 Mus musculus 0-5 12169659-0 2002 PTP1B antisense oligonucleotide lowers PTP1B protein, normalizes blood glucose, and improves insulin sensitivity in diabetic mice. Oligonucleotides 16-31 protein tyrosine phosphatase, non-receptor type 1 Mus musculus 39-44 12169659-2 2002 PTP1B antisense oligonucleotide treatment normalized plasma glucose levels, postprandial glucose excursion, and HbA(1C). Oligonucleotides 16-31 protein tyrosine phosphatase, non-receptor type 1 Mus musculus 0-5 12477292-4 2001 Genetically-modified mice that lack PTP1B protein expression and animals treated with a specific PTP1B antisense oligonucleotide have provided crucial "proof-of-concept" data to show that eradicating or reducing PTP1B enhances insulin signaling and glucose tolerance. Oligonucleotides 113-128 protein tyrosine phosphatase, non-receptor type 1 Mus musculus 97-102 12477292-4 2001 Genetically-modified mice that lack PTP1B protein expression and animals treated with a specific PTP1B antisense oligonucleotide have provided crucial "proof-of-concept" data to show that eradicating or reducing PTP1B enhances insulin signaling and glucose tolerance. Oligonucleotides 113-128 protein tyrosine phosphatase, non-receptor type 1 Mus musculus 97-102